ExoFlo™
All-Cause Acute Respiratory Distress Syndrome (ARDS)
Key Facts
About Direct Biologics
Direct Biologics is a private, clinical-stage biotech company founded in 2017 and headquartered in Austin, Texas. It is a pioneer in developing extracellular vesicle (EV)-based therapeutics, with a lead program, ExoFlo™, in Phase 3 trials for ARDS and earlier-stage trials for Crohn's disease and ulcerative colitis. The company has secured significant regulatory designations like RMAT, operates its own cGMP manufacturing, and is positioning itself as a leader in the emerging EV therapeutics space. Its business model is focused on therapeutic development, and it is currently in a pre-revenue stage.
View full company profileAbout Direct Biologics
Direct Biologics is a private, clinical-stage biotech company founded in 2017 and headquartered in Austin, Texas. It is a pioneer in developing extracellular vesicle (EV)-based therapeutics, with a lead program, ExoFlo™, in Phase 3 trials for ARDS and earlier-stage trials for Crohn's disease and ulcerative colitis. The company has secured significant regulatory designations like RMAT, operates its own cGMP manufacturing, and is positioning itself as a leader in the emerging EV therapeutics space. Its business model is focused on therapeutic development, and it is currently in a pre-revenue stage.
View full company profileAbout Direct Biologics
Direct Biologics is a private, clinical-stage biotech company founded in 2017 and headquartered in Austin, Texas. It is a pioneer in developing extracellular vesicle (EV)-based therapeutics, with a lead program, ExoFlo™, in Phase 3 trials for ARDS and earlier-stage trials for Crohn's disease and ulcerative colitis. The company has secured significant regulatory designations like RMAT, operates its own cGMP manufacturing, and is positioning itself as a leader in the emerging EV therapeutics space. Its business model is focused on therapeutic development, and it is currently in a pre-revenue stage.
View full company profile